FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074718178> ?p ?o ?g. }

• W2074718178 endingPage "498" @default.
• W2074718178 startingPage "483" @default.
• W2074718178 abstract "Metformin is an established first-line treatment for type 2 diabetes mellitus (T2DM) patients but intensification of oral anti-diabetic therapy is usually required over time. The effectiveness of diabetes control with vildaGliptin and vildagliptin/mEtformin (EDGE) study compared effectiveness and safety of vildagliptin and other oral anti-diabetic drugs (OAD) in 45,868 patients worldwide with inadequately controlled T2DM by monotherapy under real-life conditions. Here, we present effectiveness results for patients receiving vildagliptin (vildagliptin cohort) or another OAD (comparator cohort) add-on to monotherapy in Bulgaria. The eligible diabetes patients inadequately controlled with current monotherapy were assigned to add-on treatment, which was chosen by the physician based on patient’s need. Effectiveness was assessed by glycated hemoglobin (HbA1c) drop and by means of a composite endpoint assessing the proportion of patients responding to treatment (HbA1c <7%) without proven hypoglycemic event and significant weight gain (>5%) after 12 months of treatment. In total, 754 patients were enrolled in Bulgaria, 384 in the vildagliptin cohort and 369 in the comparator cohort. Mean HbA1c change from baseline was significantly higher with vildagliptin compared to the comparator (−1.35% in the vildagliptin cohort and −0.55% in the comparator cohort, P < 0.001). In the vildagliptin cohort, a higher proportion of patients reached the composite endpoint (HbA1c <7%, no hypoglycemic events, no weight gain) when compared to the comparator cohort (vildagliptin: 32.3%; comparator: 8.4%; P < 0.001). Overall, vildagliptin was well tolerated with similarly low incidences of total adverse events (3.4% versus 1.9% in the comparator group) and serious adverse events (2.3% versus 1.1% in the comparator group). In real-life clinical practice in Bulgaria, vildagliptin is associated with a greater HbA1c drop, and a higher proportion of patients reaching target HbA1c without hypoglycemia and weight gain compared to comparator." @default.
• W2074718178 created "2016-06-24" @default.
• W2074718178 creator A5044288654 @default.
• W2074718178 date "2014-09-23" @default.
• W2074718178 modified "2023-10-09" @default.
• W2074718178 title "Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data" @default.
• W2074718178 cites W1526927233 @default.
• W2074718178 cites W1577017609 @default.
• W2074718178 cites W172609984 @default.
• W2074718178 cites W1965926642 @default.
• W2074718178 cites W1975588287 @default.
• W2074718178 cites W1977619586 @default.
• W2074718178 cites W1983130067 @default.
• W2074718178 cites W1987071918 @default.
• W2074718178 cites W1991951001 @default.
• W2074718178 cites W1997334382 @default.
• W2074718178 cites W2016298811 @default.
• W2074718178 cites W2018597760 @default.
• W2074718178 cites W2024127533 @default.
• W2074718178 cites W2027249582 @default.
• W2074718178 cites W2028317115 @default.
• W2074718178 cites W2036387352 @default.
• W2074718178 cites W2055753691 @default.
• W2074718178 cites W2060083804 @default.
• W2074718178 cites W2063362369 @default.
• W2074718178 cites W2064978103 @default.
• W2074718178 cites W2071652229 @default.
• W2074718178 cites W2076336056 @default.
• W2074718178 cites W2086588588 @default.
• W2074718178 cites W2101244337 @default.
• W2074718178 cites W2103828712 @default.
• W2074718178 cites W2109728760 @default.
• W2074718178 cites W2118828750 @default.
• W2074718178 cites W2124465362 @default.
• W2074718178 cites W2136892596 @default.
• W2074718178 cites W2144125787 @default.
• W2074718178 cites W2147764623 @default.
• W2074718178 cites W2157549710 @default.
• W2074718178 cites W2158312041 @default.
• W2074718178 cites W2158666727 @default.
• W2074718178 cites W2161596956 @default.
• W2074718178 cites W2162037642 @default.
• W2074718178 cites W2164733897 @default.
• W2074718178 cites W2172193326 @default.
• W2074718178 cites W2325639638 @default.
• W2074718178 cites W2337454357 @default.
• W2074718178 cites W2472989630 @default.
• W2074718178 cites W2510708214 @default.
• W2074718178 cites W2554729258 @default.
• W2074718178 cites W4248616200 @default.
• W2074718178 cites W4255037836 @default.
• W2074718178 doi "https://doi.org/10.1007/s13300-014-0083-x" @default.
• W2074718178 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4269645" @default.
• W2074718178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25245616" @default.
• W2074718178 hasPublicationYear "2014" @default.
• W2074718178 type Work @default.
• W2074718178 sameAs 2074718178 @default.
• W2074718178 citedByCount "2" @default.
• W2074718178 countsByYear W20747181782017 @default.
• W2074718178 crossrefType "journal-article" @default.
• W2074718178 hasAuthorship W2074718178A5044288654 @default.
• W2074718178 hasBestOaLocation W20747181781 @default.
• W2074718178 hasConcept C126322002 @default.
• W2074718178 hasConcept C134018914 @default.
• W2074718178 hasConcept C197934379 @default.
• W2074718178 hasConcept C2776453732 @default.
• W2074718178 hasConcept C2777180221 @default.
• W2074718178 hasConcept C2777538456 @default.
• W2074718178 hasConcept C2778375690 @default.
• W2074718178 hasConcept C2779306644 @default.
• W2074718178 hasConcept C2780323712 @default.
• W2074718178 hasConcept C555293320 @default.
• W2074718178 hasConcept C71924100 @default.
• W2074718178 hasConcept C72563966 @default.
• W2074718178 hasConceptScore W2074718178C126322002 @default.
• W2074718178 hasConceptScore W2074718178C134018914 @default.
• W2074718178 hasConceptScore W2074718178C197934379 @default.
• W2074718178 hasConceptScore W2074718178C2776453732 @default.
• W2074718178 hasConceptScore W2074718178C2777180221 @default.
• W2074718178 hasConceptScore W2074718178C2777538456 @default.
• W2074718178 hasConceptScore W2074718178C2778375690 @default.
• W2074718178 hasConceptScore W2074718178C2779306644 @default.
• W2074718178 hasConceptScore W2074718178C2780323712 @default.
• W2074718178 hasConceptScore W2074718178C555293320 @default.
• W2074718178 hasConceptScore W2074718178C71924100 @default.
• W2074718178 hasConceptScore W2074718178C72563966 @default.
• W2074718178 hasIssue "2" @default.
• W2074718178 hasLocation W20747181781 @default.
• W2074718178 hasLocation W20747181782 @default.
• W2074718178 hasLocation W20747181783 @default.
• W2074718178 hasLocation W20747181784 @default.
• W2074718178 hasOpenAccess W2074718178 @default.
• W2074718178 hasPrimaryLocation W20747181781 @default.
• W2074718178 hasRelatedWork W159171328 @default.
• W2074718178 hasRelatedWork W2099305220 @default.
• W2074718178 hasRelatedWork W2117762041 @default.
• W2074718178 hasRelatedWork W2124465362 @default.
• W2074718178 hasRelatedWork W2291282341 @default.

• next